TG Therapeutics (TGTX) Competitors $31.15 +0.83 (+2.74%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends TGTX vs. CCXI, ARNA, APLS, PTCT, LEGN, TEVA, BGNE, VTRS, SMMT, and MRNAShould you be buying TG Therapeutics stock or one of its competitors? The main competitors of TG Therapeutics include ChemoCentryx (CCXI), Arena Pharmaceuticals (ARNA), Apellis Pharmaceuticals (APLS), PTC Therapeutics (PTCT), Legend Biotech (LEGN), Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Viatris (VTRS), Summit Therapeutics (SMMT), and Moderna (MRNA). These companies are all part of the "medical" sector. TG Therapeutics vs. ChemoCentryx Arena Pharmaceuticals Apellis Pharmaceuticals PTC Therapeutics Legend Biotech Teva Pharmaceutical Industries BeiGene Viatris Summit Therapeutics Moderna TG Therapeutics (NASDAQ:TGTX) and ChemoCentryx (NASDAQ:CCXI) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, valuation, analyst recommendations, media sentiment, dividends, profitability and risk. Does the MarketBeat Community favor TGTX or CCXI? TG Therapeutics received 314 more outperform votes than ChemoCentryx when rated by MarketBeat users. Likewise, 76.73% of users gave TG Therapeutics an outperform vote while only 57.48% of users gave ChemoCentryx an outperform vote. CompanyUnderperformOutperformTG TherapeuticsOutperform Votes65676.73% Underperform Votes19923.27% ChemoCentryxOutperform Votes34257.48% Underperform Votes25342.52% Do analysts rate TGTX or CCXI? TG Therapeutics currently has a consensus target price of $37.67, indicating a potential upside of 20.92%. Given TG Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe TG Therapeutics is more favorable than ChemoCentryx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TG Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83ChemoCentryx 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk & volatility, TGTX or CCXI? TG Therapeutics has a beta of 2.19, meaning that its share price is 119% more volatile than the S&P 500. Comparatively, ChemoCentryx has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500. Which has better valuation & earnings, TGTX or CCXI? TG Therapeutics has higher revenue and earnings than ChemoCentryx. TG Therapeutics is trading at a lower price-to-earnings ratio than ChemoCentryx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTG Therapeutics$233.66M20.75$12.67M-$0.10-311.47ChemoCentryx$32.22M115.14-$131.76M-$1.89-27.51 Is TGTX or CCXI more profitable? TG Therapeutics has a net margin of -5.42% compared to ChemoCentryx's net margin of -357.01%. TG Therapeutics' return on equity of -8.32% beat ChemoCentryx's return on equity.Company Net Margins Return on Equity Return on Assets TG Therapeutics-5.42% -8.32% -3.40% ChemoCentryx -357.01%-48.52%-30.59% Does the media favor TGTX or CCXI? In the previous week, TG Therapeutics had 5 more articles in the media than ChemoCentryx. MarketBeat recorded 5 mentions for TG Therapeutics and 0 mentions for ChemoCentryx. TG Therapeutics' average media sentiment score of 1.26 beat ChemoCentryx's score of 0.19 indicating that TG Therapeutics is being referred to more favorably in the media. Company Overall Sentiment TG Therapeutics Positive ChemoCentryx Neutral Do institutionals & insiders believe in TGTX or CCXI? 58.6% of TG Therapeutics shares are held by institutional investors. Comparatively, 81.1% of ChemoCentryx shares are held by institutional investors. 10.5% of TG Therapeutics shares are held by insiders. Comparatively, 8.3% of ChemoCentryx shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryTG Therapeutics beats ChemoCentryx on 15 of the 18 factors compared between the two stocks. Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get TG Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TGTX vs. The Competition Export to ExcelMetricTG TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.85B$6.41B$5.01B$8.81BDividend YieldN/A8.11%5.16%4.06%P/E Ratio-311.4710.57134.3717.77Price / Sales20.75243.641,158.6875.18Price / Cash337.8922.1633.5332.53Price / Book29.395.474.674.68Net Income$12.67M$153.61M$119.07M$226.08M7 Day Performance0.99%-2.00%-1.83%-1.04%1 Month Performance27.82%-7.47%-3.62%1.04%1 Year Performance152.84%31.80%31.63%26.28% TG Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TGTXTG Therapeutics4.2148 of 5 stars$31.15+2.7%$37.67+20.9%+143.0%$4.85B$233.66M-311.47290Positive NewsCCXIChemoCentryx0.7514 of 5 stars$51.99flatN/A+0.0%$3.71B$32.22M-27.51178ARNAArena PharmaceuticalsN/A$99.99flatN/A+0.0%$6.17B$50,000.00-9.87448APLSApellis Pharmaceuticals4.5973 of 5 stars$27.49-5.2%$51.06+85.7%-44.5%$3.42B$396.59M-13.54702PTCTPTC Therapeutics2.5538 of 5 stars$41.96+6.6%$42.00+0.1%+89.3%$3.04B$937.82M0.001,410Analyst DowngradeLEGNLegend Biotech1.7588 of 5 stars$40.14+4.5%$81.46+102.9%-33.7%$7.32B$520.18M-42.251,800Analyst RevisionHigh Trading VolumeTEVATeva Pharmaceutical Industries2.6924 of 5 stars$17.03+1.2%$19.67+15.5%+80.0%$19.04B$15.85B0.0037,851BGNEBeiGene3.174 of 5 stars$194.26+3.5%$247.07+27.2%+3.4%$18.92B$2.46B-23.5810,600Analyst DowngradeGap UpVTRSViatris1.3448 of 5 stars$13.13+0.6%$13.33+1.5%+38.6%$15.67B$15.05B-17.7438,000SMMTSummit Therapeutics1.863 of 5 stars$18.62-6.9%$34.75+86.6%+835.7%$14.75B$700,000.000.00105Analyst ForecastMRNAModerna4.6267 of 5 stars$36.94-0.9%$84.00+127.4%-53.2%$14.22B$6.85B-6.355,600Analyst UpgradeAnalyst Revision Related Companies and Tools Related Companies ChemoCentryx Alternatives Arena Pharmaceuticals Alternatives Apellis Pharmaceuticals Alternatives PTC Therapeutics Alternatives Legend Biotech Alternatives Teva Pharmaceutical Industries Alternatives BeiGene Alternatives Viatris Alternatives Summit Therapeutics Alternatives Moderna Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TGTX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TG Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TG Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
